Germany

In clinical practice, a variety of cognitive tests are used. The Mini-Mental State Examination (MMSE) and the Clock-Drawing Test (CDT) are still widely employed, particularly in primary care. However, German S3 guidelines and specialists also utilise more sensitive tests for detecting early-stage impairment, such as the Montreal Cognitive Assessment (MoCA), German-developed DemTect, as well as CERAD NAB+.

Germany does not have a national, organised screening programme for the general asymptomatic population.

Structural imaging with either CT or MRI is a routine and guideline-recommended part of the diagnostic process, if Alzheimer’s disease is suspected. Its primary function is to rule out other structural causes of cognitive symptoms, such as brain tumors, subdural hematomas, hydrocephalus, or evidence of a major stroke.

Advanced molecular imaging, specifically Amyloid-PET, is available, particularly at university hospitals. Tau-PET imaging is available only in limited research settings.

Testing for the rare, deterministic gene mutations that cause familial Alzheimer’s disease (APP, PSEN1, PSEN2) is available when medically indicated, for example, in cases of early disease onset. This process is strictly regulated by the German Gene Diagnostics Act, which mandates comprehensive genetic counseling before and after the test.

ApoE4 genetic test is mandatory in Germany prior to initiating treatment with Lecanemab.

CSF analysis is the established and reimbursed gold standard for confirming the biological signs of Alzheimer’s disease in Germany. The measurement of core biomarkers—the Aβ42/Aβ40 ratio and tau proteins—is recommended in the national S3 guidelines for an early and accurate diagnosis.

Advanced blood-based biomarker tests, such as those measuring plasma p-Tau217, are technically available in Germany through specialised laboratories and comply with European regulations. However, these tests are not yet part of routine clinical practice, and are not included in the official diagnostic guidelines.

There are around 160 memory clinics and consultation facilities in Germany. Their role extends beyond simple diagnosis; they develop comprehensive care plans and serve as a central hub in the regional care network, working in close cooperation with inpatient psychiatric and geriatric facilities, day-care centres, and physicians in private practice to ensure a smooth transition for patients into the care system. They are predominantly located in major cities and are typically affiliated with university hospitals, such as the Charité in Berlin or the university clinics in Tübingen and Mannheim. These clinics can be reached within an hour in nearly all (90%) parts of the country. The main exceptions are regions in the northeast, where some individuals may face travel times of up to 120 minutes. Specialised institutions like the German centre for Neurodegenerative Diseases (DZNE) located in Bonn, with additional sites in Berlin, Dresden, Göttingen, Magdeburg, Munich, Rostock/Greifswald, Tübingen, Ulm, and Witten actively collaborate with university hospitals, supporting translational research and setting high standards for care.

Community-based services are more widely distributed across the country. Day care centres offer structured activities and professional care during the day, providing respite for family caregivers and social engagement for individuals with dementia. A less common but available alternative is Night Care, which provides overnight supervision in a facility for individuals who are particularly restless or disoriented at night, ensuring their safety and allowing family caregivers to get necessary sleep. In-home support provides professional nursing and household assistance directly in the patient’s home, with many services employing staff with specialised gerontopsychiatric training. Demenzhilfe Deutschland has a national database to help families locate specialised care providers in their area.

An increasingly popular alternative to traditional nursing homes are dementia shared-living communities, where a small group of residents live together in a shared apartment with 24/7 care provided by a contracted nursing service.

Palliative care, which focuses on comfort and quality of life in the advanced stages of Alzheimer’s disease, is available throughout Germany in various settings. Specialised Ambulatory Palliative Care (SAPV) teams provide 24/7 intensive support at home or in nursing facilities to manage complex symptoms. For inpatient needs, there are palliative care units within hospitals for short-term symptom stabilisation and independent, home-like hospices for end-of-life care. Accessibility is facilitated by the German Society for Palliative Medicine (DGP), offering a national online directory listing over 3,000 services.

The costs for medically necessary medicines and therapies (e.g., occupational therapy) are covered by the Statutory Health Insurance (GKV). However, patients are required to make a co-payment for these services. When a doctor prescribes medication on a standard “pink prescription”, the GKV covers the majority of the cost. The patient is responsible for a co-payment, which is calculated as 10% of the drug’s price. This co-payment has a minimum of €5 and a maximum of €10 per medication. They will never pay more than the actual cost of the drug. For prescribed therapies, the patient’s co-payment is 10% of the total cost of the therapy sessions, plus an additional fee of €10 for each individual prescription.

Assistance with daily living (e.g., personal hygiene, mobility, supervision) is funded by the separate Long-Term Care Insurance (LTCI). The LTCI is designed as a partial-cost insurance; it provides fixed monthly subsidies but does not cover the full cost of care. To receive benefits, a patient must undergo a formal assessment to determine their level of dependency, which results in a Care Grade (from 1 to 5). The higher the grade, the greater the financial support. The LTCI provides benefits for both care at home (either as a cash payment or a larger budget for professional services) and for residential nursing homes.

However, families still face considerable financial strain, primarily through indirect costs. To provide the necessary informal care, family members often have to reduce their working hours or leave their jobs entirely. This leads to a substantial loss of income. One study estimated that caregivers in Germany earn, on average, €56,967 less over the patient’s lifetime compared to their peers in the general population. In a cohort with early-onset Alzheimer’s disease, lifetime incremental fiscal losses were projected to reach €118,533 ($114,209) per person living with Alzheimer’s disease.

To provide relief, caregivers can utilise a unified annual budget of €3,539 for both home-based respite care (Verhinderungspflege) and institutional short-term care (Kurzzeitpflege). This flexible budget can be used for up to eight weeks of care per year, and the previous six-month prior care requirement for accessing respite care has been eliminated. A universal monthly relief budget (Entlastungsbetrag) of €131 is also available to reimburse costs for services that relieve caregivers, such as day care or household help. Additionally, long-term care funds are required to offer free training courses (Pflegekurse) that cover practical nursing skills, stress management, and guidance on navigating the care system.

To protect caregivers’ financial security, the Long-Term Care Insurance (LTCI) pays pension contributions for those providing at least 10 hours of care per week for someone with care grade 2 or higher. Unpaid caregivers can also claim an annual tax deduction (Pflege-Pauschbetrag) of €600 for care grade 2, €1,100 for care grade 3, and €1,800 for care grades 4 or 5.

Finally, German labour law provides job protection through statutory leave, including short-term emergency leave of up to 10 days, extended care leave (Pflegezeit) of up to six months, and family care leave (Familienpflegezeit), which allows for reduced working hours for up to 24 months.

The German Alzheimer Society provides specific support for caregivers. Through their network of over 130 local associations across the country, they organise caregiver support groups. They also developed “Help with Helping”, a free training course specifically for caregivers of people living with dementia. These courses cover essential topics such as understanding the illness, legal and insurance matters, managing difficult situations, and strategies for caregiver self-care and relief.

Germany’s National Dementia Strategy, officially launched in 2020, is built around four core fields of action, designed to improve the lives of individuals living with dementia and their caregivers across the country:

1. Developing and establishing dementia-inclusive communities to enable people living with dementia to participate in society: The goal is to strengthen local and regional networks so that people with dementia can remain active and visible in society. This includes expanding local alliances, improving financial and structural support, and raising public awareness to foster understanding, reduce stigma, and promote participation in everyday community life.
2. Supporting people living with dementia and their caregivers: The strategy emphasises the need for guidance and orientation through volunteer guides and professional companions, while also promoting programs that help families balance employment and caregiving responsibilities. Preventive measures are designed to protect caregivers from burnout, ensuring that both those with dementia and those who support them receive reliable and continuous assistance.
3. Advancing health and long-term care services for people living with dementia: The emphasis is on creating dementia-sensitive environments in hospitals and nursing homes, improving staffing levels, and coordinating care more effectively across providers. By focusing on streamlined care pathways and preventive health measures, the strategy seeks to guarantee that people living with dementia receive high-quality, consistent, and person-centered treatment throughout all stages of the condition.
4. Promoting excellent research on dementia: This includes fostering stronger collaboration among German research institutions, establishing a national research network, and building connections within Europe. Research is not limited to biomedical innovation but also extends to diagnosis, treatment concepts, and caregiving approaches, ensuring that new knowledge is quickly translated into better care and support for those affected.

Germany is making major steps towards implementation of Alzheimer’s disease blood tests, which are currently evaluated in specialty laboratories across the country. The DELCODE project, for example, aims to find ways of detecting Alzheimer’s disease early, as soon as the first minor symptoms appear, or even before any symptoms at all have appeared. Researchers from across the country are using the longitudinal cohort from the DELCODE project to study subjective cognitive decline and prodromal Alzheimer’s disease to validate plasma and CSF biomarkers and prediction tools. Additionally, a 2025 DZNE multicenter project is evaluating smartphone memory tests (via the neotiv app) in ~30 practices to detect mild cognitive impairment earlier and aid clinical decision-making.

DZNE is also conducting the Rhineland Study, a large-scale, long-term population study following up to 20,000 people to identify risk and protective factors for dementia. The goal is to understand the interplay of genetic, lifestyle, and environmental factors to improve prevention strategies for age-related diseases.

DZNE and the Hertie Institute for Clinical Brain Research (HIH) in Tübingen are leading the AlzBiom study, a longitudinal project investigating the role of the gut microbiome across different stages of Alzheimer’s disease. The study aims to identify a specific “Alzheimer signature” in the microbiome that could serve as a non-invasive biomarker for early disease detection and a target for new therapies.

The AgeWell.de trial—led by University of Leipzig and funded by the German Federal Ministry of Education and Research—is a two-year, multi-centre German study evaluating a multi-component lifestyle intervention for older adults (60-77 years) at increased dementia risk. It found no effect on global cognition, but did reduce dementia-risk profiles, improve health-related quality of life and lower depressive symptoms in women.

Centre for Protein Diagnostics (PRODI) at Ruhr University Bochum received the NRW Innovation Prise in 2023 for developing a biomarker blood test that can predict later onset of the disease up to 17 years before the onset of clinical Alzheimer’s disease symptoms (i.e., in asymptomatic patients). This prognostic test determines the increase in misfolded, toxic amyloid beta proteins.

Researchers from several leading institutions (e.g., LMU Munich, Charité Berlin, etc) are working on rapid, AI-based brain volumetry shown to improve dementia differential diagnosis in clinic settings.

Researchers at the Technical University of Munich target early amyloid-driven neuronal hyperactivity to halt or reverse early-stage Alzheimer’s disease pathology.

Researchers are exploring sTREM2 as both a dynamic biomarker for tracking disease progression and a promising target for immune-based interventions. Longitudinal data from autosomal‐dominant Alzheimer’s disease families show that rising levels of CSF soluble TREM2 (sTREM2) correlate with slower amyloid accumulation, reduced cortical shrinkage, and slower cognitive decline—suggesting that TREM2 activation may play a protective role in early disease stages.

A comprehensive list of all research led by DZNE is available at:
https://www.dzne.de/en/research/studies/clinical-studies/studyfilter/